• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21642 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid cancer) - Addendum to Commission A22-59]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brexucabtagene autoleucel (acute lymphatic r/r B cell leukemia, from 26 years of age) - Assessment according to §35a SGB V (1), Sentence 11]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Birch bark extract (epidermolysis bullosa) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51]
2022     Health Sciences Institute in Aragon (IACS) [Non-perforating deep sclerectomy (NPDS) in open angle primary glaucoma (POAG)]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of convalescent plasma donor therapy in the treatment of COVID-19]
2022     Health Technology Wales (HTW) Wearable cardioverter-defibrillators for people at risk of cardiac death
2022     Health Technology Wales (HTW) Photobiomodulation for the prevention and treatment of oral mucositis and radiation dermatitis associated with cancer treatment
2022     Health Technology Wales (HTW) Closed loop systems for the management of type 1 diabetes mellitus in adults and children
2022     Health Technology Wales (HTW) Continuous topical oxygen therapy to treat people with chronic non-healing and complex diabetic foot ulcers
2022     Health Technology Wales (HTW) Left atrial appendage occlusion in patients with atrial fibrillation
2022     Malaysian Health Technology Assessment (MaHTAS) Mesenchymal stem cells for retinitis pigmentosa and other degenerative retina disease
2022     Malaysian Health Technology Assessment (MaHTAS) Sublingual immunotherapy (SLIT) for atopy (allergic rhinitis, eczema and asthma)
2022     Malaysian Health Technology Assessment (MaHTAS) Transcutaneous oxygen pressure monitoring (TcPO2)
2022     Malaysian Health Technology Assessment (MaHTAS) First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022     Gesundheit Osterreich GmbH (GOeG) [Cost effectiveness of communication training for health care professionals]
2022     Malaysian Health Technology Assessment (MaHTAS) Early cancer detection test for lung (EarlyCDT-Lung)
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Perinatal and infant mental health care models and pathways
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022     NIHR Health Services and Delivery Research programme Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature
2022     NIHR Health Technology Assessment programme Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
2022     NIHR Health Technology Assessment programme Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2022     WorkSafeBC Ketamine infusion therapy for hyperalgesia and or central sensitivity pain
2022     WorkSafeBC Percussion therapy for neuropathic pain
2022     WorkSafeBC Dupuytren's contracture and wrist fractures
2022     WorkSafeBC Functional neurology as treatment for post-traumatic brain injury
2022     WorkSafeBC Clinical accuracy of rapid antigen tests for COVID-19
2022     NIHR Health Technology Assessment programme EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation
2022     Penn Medicine Center for Evidence-based Practice (CEP) Peripartum or postnatal care disparities and equity
2022     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines and clinical pathways for management of upper GI bleeding
2022     Penn Medicine Center for Evidence-based Practice (CEP) Medications for treating moderate to severe alcohol withdrawal syndrome in critical care and emergency department patients
2022     Austrian Institute for Health Technology Assessment (AIHTA) Quality registries in dementia care: mapping of registries to improve quality and service delivery
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposures and asthma and COPD]
2022     Norwegian Institute of Public Health (NIPH) [Intravenous ketamine for treatment-resistant depression and suicidal ideation: a single technology assessment - mapping]
2022     WorkSafeBC Satir brief transformational therapy as treatment for trauma-related disorders including PTSD
2022     WorkSafeBC Balloon spacer as treatment for massive rotator cuff tear
2022     WorkSafeBC SANUWAVE therapy for wound healing
2022     WorkSafeBC Antalgic gait, limp, osteoarthritis - what happens to the weight-bearing joints?
2022     WorkSafeBC N-acetylcysteine (NAC) as treatment for complex regional pain syndrome (CRPS): 2022 Update
2022     Health Information and Quality Authority (HIQA) COVID-19 Evidence Synthesis: International review of guidance on the use of face masks to mitigate the spread of SARS-CoV-2 infection
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: RASopathies Next-generation Sequencing Panel]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Child and adolescent mental health care models: a scoping review
2022     Belgian Health Care Knowledge Centre (KCE) Evaluation of Shingrix vaccine against herpes zoster
2022     NIHR Health Technology Assessment programme SeHCAT (tauroselcholic [75selenium] acid) for the investigation of bile acid diarrhoea in adults: a systematic review and cost-effectiveness analysis
2022     Austrian Institute for Health Technology Assessment (AIHTA) Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 3 - overview of renal and pancreatic transplantation in Québec]
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE)
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: revision of criteria for the withholding and termination of resuscitation by paramedics in prehospital setting]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - eye surgery]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - otolaryngology and oral, maxillofacial and head and neck surgery]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - vascular, cardiovascular and thoracic surgery]
2022     Center for Drug Evaluation (CDE) First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
2022     NIHR Health Technology Assessment programme Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacotherapy in the treatment of obesity]
2022     Health Information and Quality Authority (HIQA) Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022     Health Information and Quality Authority (HIQA) Catalogue of institutions undertaking COVID-19 horizon scanning
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions – Part 1: Urinary incontinence]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Vistaseal™ – Intraoperative bleeding]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological Treatment for Postpartum Depression]
2022     Andalusian Health Technology Assessment Area (AETSA) Marcapasos sin cable con sincronía aurículo- ventricular para el tratamiento del bloqueo aurículo-ventricular. Actualización.
2022     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways and structures: an updated scoping review
2022     Austrian Institute for Health Technology Assessment (AIHTA) Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotrovimab (COVID-19, without supplemental oxygen, increased risk of severe disease) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (visual impairment due to diabetic macular oedema) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of age limits in the mammography screening programme]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]